AstraZeneca and Absci Collaborate on AI-Driven Cancer Therapy Development

AstraZeneca and Absci Collaborate on AI-Driven Cancer Therapy Development
1.8BUSD

See which Billionaires own this investment
Type
Common Stock
Exchange
NASDAQ
Currency Code
USD
Currency Name
US Dollar
Country Name
USA
Country ISO
US
ISIN
US00091E1091
CUSIP
00091E109
Sector
Healthcare
Industry
Biotechnology
Fiscal Year End
December
IPO date
-
Updated At
-
PE Ratio
-
PEG Ratio
-
Book Value
1.11
Dividend Share
-
Dividend Yield
-
Earnings Share
-0.82
Wall Street Target Price
13.78
EPS Estimate Current Year
-0.78
EPS Estimate Next Year
-0.62
EPS Estimate Current Quarter
-0.1992
EPS Estimate Next Quarter
-0.2038
Most Recent Quarter
-
Revenue TTM
1,836,000
Gross Profit TTM
-81,793,000
EBITDA
-116,437,000
Profit Margin
0.00%
Return On Assets TTM
-37.33%
Return On Equity TTM
-63.89%
Revenue Per Share TTM
0.013
Qtly Revenue Growth YOY
-81.80%
Diluted Eps TTM
-0.82
Qtly Earnings Growth YOY
0.00%
Trailing PE
0.00
Forward PE
0
Price Sales TTM
978.0194
Price Book MRQ
10.4366
Enterprise Value Revenue
911
Enterprise Value EBITDA
0
21.58
2.27%186.52
0.87%282.00
0.16%935.38
0.00%86.38
0.00%271.69
-2.74%132.25
-1.37%657.00
-0.94%476.99
-0.69%855.90
-0.33%